What's Happening?
Panome Bio, a multi-omics contract research organization, has announced a strategic partnership with Audubon Bioscience, a global biospecimen provider. This collaboration aims to streamline the process for cancer researchers by providing a coordinated
pathway from ethically sourced formalin-fixed paraffin-embedded (FFPE) tissue procurement to comprehensive discovery metabolomics. The partnership introduces Panome's TissueBridge™ FFPE Metabolomics platform, which integrates into existing pathology workflows, offering researchers a reliable path from tissue acquisition to metabolic profiling. This initiative is expected to accelerate biomarker discovery and the identification of novel drug targets from clinical archives.
Why It's Important?
The partnership between Panome Bio and Audubon Bioscience is significant for the field of cancer research as it addresses a longstanding bottleneck in accessing and utilizing FFPE tissue samples for metabolomics. By providing a seamless integration of tissue procurement and metabolic analysis, researchers can leverage decades of collected FFPE tissue to gain deeper biological insights. This collaboration enhances the potential for breakthroughs in diagnostics and treatment, offering a new dimension of biological insight to archived tissue. It represents a step forward in making metabolomics a practical and profitable part of modern cancer research.
What's Next?
Panome Bio and Audubon Bioscience will be showcasing their partnership at the AACR Annual Meeting 2026 in San Diego, California. Researchers interested in learning more about the TissueBridge™ FFPE Metabolomics platform and the partnership are encouraged to visit their booth or contact the team for further information. The collaboration is expected to pave the way for future innovations and joint projects, potentially funded by Innovate UK, to drive further advancements in cancer research.
